Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(10 sites)
United States
Arizona Urology Specialists, Tucson, Arizona University of Florida, Gainesville, Florida Beth Israel Deaconess Medical Center, Boston, Massachusetts Duke Cancer Center, Durham, North Carolina The Ohio State University, Columbus, Ohio Carolina Urologic Research Center, Myrtle Beach, South Carolina Urology Associates, P.C., Nashville, Tennessee University of Texas Southwestern Medical Center, Dallas, Texas Baylor College of Medicine, Houston, Texas Houston Methodist, Houston, Texas